Welsh P, et al. - Prognostic value of emerging biomarkers was tested in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial. In patients with chronic heart failure with reduced ejection fraction patients and moderate anaemia, once N-terminal pro-B-type natriuretic peptide (NT-proBNP) was included, only high-sensitivity troponin T (hsTnT) moderately further improved risk stratification. As a predictor of adverse outcome, NT-proBNP and hsTnT far outperformed other emerging biomarkers.